Safety of drugs used in the treatment of osteoporosis

Therapeutic Advances in Drug Safety

Volumn 2, Issue 4, 2011, Pages 159-172

  McGreevy, Cora ^a   Williams, David ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

adverse effects; bisphosphonates; drug safety; osteoporosis; recombinant human parathyroid hormone; strontium; vitamin D

Indexed keywords

EID: 84993683523     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098611411012     Document Type: Review

References (74)

1. Abrahamsen B. Eiken P. Eastell R. (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res 24: 1095–1102.
2. Ahmed S.F. Elmantaser M. (2009) Secondary osteoporosis. Endocr Dev 16: 170–190.
3. Anderson G.L. Limacher M. Assaf A.R. Bassford T. Beresford S.A. Black H. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women–s Health Initiative Randomised Controlled Trial. JAMA 291: 1701–1712.
4. Andersen M. Kukreja S. (2008) Bisphosphonates and chronic kidney disease. Kidney 17: 119–121.
5. Bischoff-Ferrari H.A. Conzelmann M. Stähelin H.B. Dick W. Carpenter M.G. Adkin A.L. (2006) Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int 17: 656–663.
6. Bischoff-Ferrari H.A. Willett W.C. Wong J.B. Stuck A.E. Staehelin H.B. Orav E.J. (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials. Arch Intern Med 169: 551–561.
7. Black D.M. Cummings S.R. Karpf D.B. Cauley J.A. Thompson D.E. Nevitt M.C. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.
8. Black D.M. Delmas P.D. Eastell R. Reid I.R. Boonen S. Cauley J.A. (2007) HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822.
9. Blair H.C. Teitelbaum S.L. Ghiselli R. Gluck S. (1989) Osteoclastic bone resorption by a polarized proton pump. Science 245: 855–857.
10. Bolland M.J. Avenell A. Baron J.A. Grey A. MacLennan G.S. Gamble G.D. (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341: c3691–c3691.
11. Bolland M.J. Hay D. Grey A. Reid I.R. Cundy T. (2006) Osteonecrosis of the jaw and bisphosphonates – putting the risk in perspective. N Z Med J 118: U2339–U2339.
12. Boonen S. Sellmeyer D.E. Lippuner K. Orlov-Morozov A. Abrams K. Mesenbrink P. (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74: 641–648.
13. Burge R.T. Worley D. Johansen A. Bhattacharyya S. Bose U. (2001) The cost of osteoporotic fractures in the UK: Projections for 2000–2020. J Med Econ 4: 51–62.
14. Cardwell C.R. Abnet C.C. Cantwell M.M. Murray L.J. (2010) Exposure to oral bisphosphonates and risk of oesophageal cancer. JAMA 304: 657–663.
15. Cauley J.A. Robbins J. Chen Z. Cummings S.R. Jackson R.D. LaCroix A.Z. (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women–s Health Initiative randomized trial. JAMA 290: 1729–1738.
16. Chaiamnuay S. Saag K.G. (2006) Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 7: 101–112.
17. Chesnut I.C. Skag A. Christiansen C. Recker R. Stakkestad J.A. Hoiseth A. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249.
18. Cleland J.G.F. Witte K. Steel S. (2010) Calcium supplements in people with osteoporosis. BMJ 341: c3856–c3856.
19. Cranney A. Tugwell P. Adachi J. Weaver B. Zytaruk N. Papaioannou A. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 517–523.
20. Cummings S.R. Black D.M. Thompson D.E. Applegate W.B. Barrett-Connor E. Musliner T. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 2077–2082.
21. Cummings S.R. Eastell R. Ensrud K. Reid D.M. Vukicevic S. Lacroix A. (2008) The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 23(Suppl. 1): S81–S81.
22. Cummings S.R. San Martin J. McClung M.R. Siris E.S. Eastell R. Reid I.R. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 391: 756–765.
23. Cunningham J. Sprague S.M. Cannata-Andia J. Coco M. Cohen-Solal M. Fitzpatrick L. Osteoporosis Work Group (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43: 566–571.
24. Dawson-Hughes B. Mithal A. Bonjour J.P. Boonen S. Burckhardt P. Fuleihan G.E. (2010) IOF position statement: Vitamin D recommendations for older adults. Osteoporos Int 21: 1151–1154.
25. Deeks E.D. Dhillon S. (2010) Spotlight on strontium ranelate: In postmenopausal osteoporosis. Drugs Aging 27: 771–773.
26. Delmas P.D. Ensrud K.E. Adachi J.D. Harper K.D. Sarkar S. Gennari C. (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87: 3609–3617.
27. Delmas P.D. Recker R.R. Chesnut E.C.H. Skag A. Stakkestad J.A. Emkey E.R. (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 15: 792–798.
28. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340: b5463– b5463.
29. Eriksen E.F. Langdahl B. Vesterby A. Rungby J. Kassem M. (1999) Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. J Bone Miner Res 14: 1217–1221.
30. Ettinger B. Black D.M. Mitlakm B.H. Knickerbocker R.K. Nickelsen T. Genant H.K. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637–645.
31. Fraunfelder F.W. Fraunfelder F.T. (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348: 1187–1188.
32. Fraunfelder F.W. Fraunfelder F.T. Jensvold B. (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135: 219–222.
33. Green J. Czanner G. Reeves G. Watson J. Wise L. Beral V. (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ 341: c4444–c4444.
34. Greenspan S.L. Bone H.G. Ettinger M.P. Hanley D.A. Lindsay R. Zanchetta J.R. (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 146: 326–339.
35. Hughes D.E. Dai A. Tiffee J.C. Li H.H. Mundy G.R. Boyce B.F. (1996) ER promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2: 1132–1136.
36. Jamal S.A. Bauer D.C. Ensrud K.E. Cauley J.A. Hochberg M. Ishani A. (2007) Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res 22: 503–508.
37. Kanis J.A. Johansson H. Oden A. McCloskey E.V. (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX(R). Bone 47: 729–735.
38. Keen R. (2007) Osteoporosis: Strategies for prevention and management. Best Pract Res Clin Rheumatol 21: 109–122.
39. Klotzbuecher C. Ross P. Landsman P. Abbott T. Berger M. (2000) Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15: 721–739.
40. Kroll M.H. (2000) Parathyroid hormone temporal effects on bone formation and resorption. Bul Math Biol 62: 163–187.
41. Lenart B.A. Lorich D.G. Lane J.M. (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 58: 1304–1306.
42. Lyles K.W. Colón-Emeric C.S. Magaziner J.S. Adachi J.D. Pieper C.F. Mautalen C. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809.
43. Macarol V. Fraunfelder F.T. (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 188: 220–224.
44. Markowitz G.S. Fine P.L. Stack J.I. Kunis C.L. Radhakrishnan J. Palecki W. (2003) Toxic acute tubular necrosis following treatment with zoledronate. Kidney Int 64: 281–289.
45. Miller P.D. Roux C. Boonen S. Barton I.P. Dunlap L.E. Burgio D.E. (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105–2215.
46. National Osteoporosis Foundation (NOF) (2010) Clinician's Guide to Prevention and Treatment of Osteoporosis, Washington, DC: National Osteoporosis Foundation.
47. Nelson H.D. Humphrey L.L. Nygren P. Teutsch S.M. Allan J.D. (2002) Postmenopausal hormone replacement therapy and risk for venous thromboembolism. JAMA 288: 872–881.
48. O'Donnell S. Cranney A. Wells G.A. Adachi J.D. Reginster J.Y. (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochr Database Syst Rev 3): CD005326–CD005326.
49. Odvina C.V. Zerwekh J.E. Rao D.S. Maalouf N. Gottschalk F.A. Park C.Y. (2005) Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294–1301.
50. Perazella M.A. Markowitz G.S. (2008) Bisphosphonate nephrotoxicity. Kidney Int 74: 1385–1393.
51. Pernicova I. Midleton E.T. Aye M. (2008) Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 19: 1811–1812.
52. Peter R. Mishra V. Fraser W.D. (2004) Severe hypocalcemia after being given intravenous bisphosphonate. BMJ 328: 335–336.
53. Pols H.A. Felsenberg D. Hanley D.A. Stepan J. Munoz-Torres M. Wilkin T.J. (1999) Multinational, placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9: 461–468.
54. Reid I.R. Ames R. Mason B. Bolland M.J. Bacon C.J. Reid H.E. (2010) Effects of calcium supplementation on lipids, blood pressure and body composition in older men: A randomised controlled trial. Am J Clin Nutr 91: 131–139.
55. Reid I.R. Brown J.P. Burckhardt P. Horowitz Z. Richardson P. Trechsel U. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653–661.
56. Rosen C.J. Hochberg M.C. Bonnick S.L. McClung M. Miller P. Broy S. (2005) Treatment with once weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20: 141–151.
57. Roussouw J.E. Anderson G.L. Prentice R.L. LaCroix A.Z. Kooperberg C. Stefanick M.L. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321–333.
58. Rustemeyer J. Bremerich A. (2010) Bisphosphonate-associated osteonecrosis of the jaw: What do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig 14: 59–64.
59. Schmidt G.A. Horner K.E. McDanel D.L. Ross M.B. Moores K.G. (2010) Risks and benefits of long-term bisphosphonate therapy. Am J Health Syst Pharm 67: 994–1001.
60. Seeman E. Boonen S. Borgström F. Vellas B. Aquino J.P. Semler J. (2010) Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 46: 1038–1042.
61. Seeman E. Delmas P.D. (2006) Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med 354: 2250–2261.
62. Shane E. Burr D. Ebeling P.R. Abrahamsen B. Adler R.A. Brown T.D. (2010) Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267–2294.
63. Silverman S.L. Christiansen C. Genant H.K. Vukicevic S. Zanchetta J.R. de Villiers T.J. (2009) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo, and active-controlled clinical trial. J Bone Miner Res 23: 1923–1934.
64. Tang B.M. Eslick G.D. Nowson C. Smith C. Bensoussan A. (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet 370: 657–666.
65. Taylor K.H. Middlefell L.S. Mizen K.D. (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 15 October [Epub ahead of print].
66. Trivedi D.P. Doll R. Khaw K. (2003) Effect of four monthly oral vitamin D supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 326: 469–475.
67. Watts N.B. Diab D.L. (2010) Long term use of bisphosphonate in osteoporosis. J Clin Endocrinol Metab 97: 1555–1565.
68. Weiss N.S. Ure C.L. Ballard J.H. Williams A.R. Daling J.R. (1980) Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303: 1195–1198.
69. Wells G. Tugwell P. Shea B. Guyatt G. Peterson J. Zytaruk N. (2002) Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrinol Rev 23: 529–539.
70. Woos S. Hellstein J. Kalmar J. (2006) Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Internal Med 144: 753–761.
71. Wysowski D.W. (2009) Reports of oesophageal cancer with oral bisphosphonate use. N Engl JMed 360: 89–90.
72. Wysowski D.W. (2010) Oral bisphosphonates and oeseophageal cancer. BMJ 341: c4506–c4506.
73. Yasuda H. Shima N. Nakagawa N. Yamaguchi K. Kinosaki M. Mochizuki S. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597–3602.
74. Zallone A. (2006) Direct and indirect oestrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 1068: 173–179.